EX VIVO Organ CONDITIONING : Introducing TBM‑005

TBM-005 is an ex vivo additive for preservation and perfusion solutions, designed to support organ quality of DCD and other high-risk donor organs exposed to ischemic stress and reperfusion-related challenges.

The untapped donor pool

With Donation after Brain Death (DBD) relatively stable, Donation after Cardiocirculatory Death (DCD) is increasingly important, but recovered DCD organs remain limited by warm ischemia, evaluation timelines, and quality criteria.

Total deaths in the US:
~3,100,000/year (~35% hospital setting)

Donation after brain death
(DBD)

Total estimated deaths:
~ 15,000 – 20,000 / yr

Total donors recovered:
~ 8,400 / yr (28 – 56%)

Total organs transplanted:
~ 26,000 / yr

Donation after cardiocirculatory death (DCD)

Total estimated deaths:
~ 800,000 – 1,000,000 / yr

Total donors recovered:
~ 8,100 / yr (0.1 – 0.8%)

Total organs transplanted:
~ 16,000 / yr

Organ utilization remains limited by ischemic injury, timing constraints, and organ-quality concerns.

Lung transplantation

DBD lungs

94%

transplanted

~3,017 lungs recovered in the US
~2,833 lungs transplanted in the US

DCD lungs

68%

transplanted

~960 lungs recovered in the US
~657 lungs transplanted in the US

Recovered DCD lungs are transplanted less often than DBD lungs, highlighting quality, timing, and assessment barriers.

SOURCE: organdonor.gov; OPTN 2025

Protecting organ quality, from recovery to transplant

Targa’s solution

A conditioning additive to support organ quality

TBM-005 is an ex vivo additive for preservation and perfusion solutions, designed to maintain / protect organ quality and reduce ischemia- and reperfusion-related stress. It is workflow-compatible and temperature-flexible, integrating into existing transplant processes without requiring new equipment or major procedural changes.

Cold PRESERVATION 4-10°C

During procurement

TBM-005 is added to flush and cold-storage solutions at organ procurement.

Warm perfusion 37°c

During EVLP

TBM-005 is integrated into machine perfusion solutions during ex vivo assessment, supporting organ conditioning while organ function is evaluated.

Key Features

Designed for preservation and perfusion workflows
Developed as an additive to existing organ recovery and perfusion solutions with no new hardware concept required
Can integrate into current procurement, storage, and ex vivo perfusion processes with temperature-flexible ex vivo use
Designed for cold preservation and warm perfusion settings
Supported by preclinical organ-recovery data

Advancing toward first-in-human
clinical validation

Clinical track record

A clinical execution platform rooted in transplant expertise

The team behind TBM-005 brings the scientific track record, institutional affiliations, and clinical infrastructure required to advance the program toward first-in-human evaluation.

First-in-human study

Targa’s Chief Medical Officer, Dr. Nicolas Noiseux, has led first-in-human trials in cell therapy for ischemic heart disease and heart failure at CHUM. The clinical team brings deep experience in translating experimental science into safe, validated human studies.

250+ peer-reviewed publications

Co-Founders Dr. Shant Der Sarkissian and Dr. Nicolas Noiseux combine deep scientific expertise with hands-on experience across cardiovascular research, cell and gene therapy, and translational medicine.

Preclinical development across multiple organ types

TBM-005 is supported by small- and large-animal data across lung, liver, and heart models. Manufacturing development activities and regulatory preparations are underway.

Workflow-compatible by design

TBM-005 is an ex vivo additive designed to integrate into existing preservation and perfusion workflows, with no new hardware required.

Clinical application

One treatment platform, multiple possibilities

Lung

Advancing toward first-in-human clinical evaluation.

Heart

Compelling data in cardiac preclinical models.

Liver

Compelling data in preclinical models of hepatic preservation/perfusion.

Kidney

Future development opportunity. Evaluation planned through scientific collaboration.

Work with us

Amplifying what your platform can already do

TBM-005 is designed to complement existing preservation and perfusion workflows as an ex vivo organ conditioning additive. It is intended to support organ quality during recovery, preservation, and perfusion without requiring new hardware or major procedural changes.

For transplant
programs & OPOs

More usable organs. No workflow disruption.

TBM-005 is designed to support organ quality in Donation after Cardiocirculatory Death (DCD) and other marginal donor organs during preservation and perfusion. It is being developed with the goal of helping to increase the availability of transplantable organs while integrating into existing transplant workflows without major procedural changes.

For device & solution
manufacturers

Strengthen your DCD program

TBM-005 is designed to integrate with existing preservation and perfusion platforms as an additive. It is not a competing device. For device and solution manufacturers, it may complement current offerings and support broader clinical utility in DCD and marginal organ use.

Frequently
Asked
Questions

What is TBM-005?Michèle2026-07-03T15:29:13-04:00

What is TBM-005?

TBM-005 is an ex vivo additive developed by Targa Biomedical for use with organ preservation and perfusion solutions and systems. It is designed to support donor organ quality prior to transplantation, including marginal organs and organs from Donation after Cardiocirculatory Death (DCD).

What is DCD organ transplantation?Michèle2026-06-30T16:16:09-04:00

What is DCD organ transplantation?

DCD stands for Donation after Cardiocirculatory Death. These are organs donated after the heart has stopped, rather than after brain death donation (DBD). Because blood flow has stopped before the organ is cooled and preserved, DCD organs may experience warm ischemia, a period of reduced oxygen delivery that can affect organ quality and transplant suitability.

What is ischemia-reperfusion injury in organ transplantation?Michèle2026-06-30T16:13:57-04:00

What is ischemia-reperfusion injury in organ transplantation?

Ischemia-reperfusion injury can occur when an organ experiences reduced oxygen delivery followed by restoration of oxygenated perfusion. This process may contribute to cellular stress, inflammation, edema, and reduced organ function. Organs from Donation after Cardiocirculatory Death (DCD), as well as other marginal and high-risk donor organs, can be particularly vulnerable due to warm ischemia, preservation conditions, and reperfusion-related stresses.

How does TBM-005 work with existing perfusion systems?Michèle2026-06-30T16:10:54-04:00

How does TBM-005 work with existing perfusion systems?

TBM-005 is being developed as an ex vivo additive intended for integration into existing organ preservation and perfusion workflows. The development approach is intended to support compatibility with current cold storage, flush, and ex vivo perfusion approaches without requiring any additional dedicated device.

What organ programs is TBM-005 being developed for?Michèle2026-06-30T16:23:29-04:00

What organ programs is TBM-005 being developed for?

TBM-005 is currently advancing toward a first-in-human clinical study in lung transplantation. Additional preclinical programs are ongoing in liver, heart, and kidney preservation and perfusion.

Accelerators and Support

Targa is actively engaging preservation and perfusion partners. If our organ rescue technology is relevant to your pipeline, reach out.

Targa is actively engaging preservation and perfusion partners. If our organ rescue technology is relevant to your pipeline, we’d like to hear from you.